Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2022
- The Future of Generics
Advertise

Search

Search

Close

Trending

Huge inequalities found in access to myeloma clinical trials in Europe, says MPE

6th Annual 3D Cell Culture Conference

SMC gives Bayer’s CKD therapy Kerendia the green light in Scotland

Can VR technology make physical therapy fun? – the pharmaphorum podcast

Steps to building a more patient-centric industry

ALL

NICE1

Cancer/ News/ UK & Europe

Pfizer objects to NICE methods in leukaemia drug rejection

Richard Staines ALL, blood cancer, leukaemia, market access, NICE, Pfizer 0 Comment

NICE has caused controversy by rejecting Pfizer’s Besponsa – a blood cancer drug that can give patients the

X

Pfizer objects to NICE methods in leukaemia drug rejection

https://pharmaphorum.com/news/pfizer-questions-nice-methods-besponsa/

Pfizer’s fast-tracked leukaemia candidate could rival CAR-Ts

Pfizer’s fast-tracked leukaemia candidate could rival CAR-Ts

Richard Staines ALL, blood cancer, cancer, Pfizer, UCB 0 Comment

Antibody-drug conjugate with FDA gets six-month review.

X

Pfizer’s fast-tracked leukaemia candidate could rival CAR-Ts

https://pharmaphorum.com/news/pfizer-files-leukaemia-antibody-us/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

Frontiers Health Steering Committee spotlight – Monique Levy

Frontiers Health Steering Committee spotlight – Monique Levy

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Most popular

Most Viewed

AstraZeneca leads winners at Reuters Pharma Awards 2022
LEO Pharma's Adtralza approved by MHRA, EC for adolescent atopic dermatitis
Two drug-related deaths reported on eve of Phase 3 lecanemab data
Another Twitter blow to science as Musk ends COVID misinformation policy
Genentech withdraws US indication of Tecentriq for bladder, urinary tract cancer

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com